These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20150620)

  • 1. Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats.
    Kim CS; Choi SJ; Park CY; Li C; Choi JS
    Anticancer Res; 2010 Jan; 30(1):79-85. PubMed ID: 20150620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
    Shin SC; Choi JS
    Anticancer Drugs; 2009 Aug; 20(7):584-8. PubMed ID: 19491656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
    Cho YA; Lee W; Choi JS
    Pharmazie; 2012 Feb; 67(2):124-30. PubMed ID: 22512082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of morin on the bioavailability of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
    Shin SC; Piao YJ; Choi JS
    In Vivo; 2008; 22(3):391-5. PubMed ID: 18610753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats.
    Li C; Lee MY; Choi JS
    Pharmazie; 2010 Jul; 65(7):510-4. PubMed ID: 20662320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats.
    Shin SC; Choi JS; Li X
    Int J Pharm; 2006 Apr; 313(1-2):144-9. PubMed ID: 16516418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
    Li C; Lim SC; Kim J; Choi JS
    Eur J Drug Metab Pharmacokinet; 2011 Sep; 36(3):175-82. PubMed ID: 21442417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein.
    Li C; Kim M; Choi H; Choi J
    Arch Pharm Res; 2011 Nov; 34(11):1965-72. PubMed ID: 22139696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced bioavailability of tamoxifen and its metabolite 4-hydroxytamoxifen after oral administration with biochanin A (an isoflavone) in rats.
    Singh SP; Wahajuddin ; Raju KS; Ali MM; Kohli K; Jain GK
    Phytother Res; 2012 Feb; 26(2):303-7. PubMed ID: 22131128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats.
    Piao Y; Shin SC; Choi JS
    Biopharm Drug Dispos; 2008 May; 29(4):245-9. PubMed ID: 18338336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin.
    Choi DH; Li C; Choi JS
    J Pharm Pharmacol; 2010 Jul; 62(7):908-14. PubMed ID: 20636879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin.
    Choi JS; Kang KW
    Arch Pharm Res; 2008 Dec; 31(12):1631-6. PubMed ID: 19099234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effect on pharmacokinetics of tamoxifen and 4-hydroxytamoxifen by multiple doses of red clover capsule in rats.
    Raju KS; Taneja I; Valicherla GR; Challagundla MK; Rashid M; Syed AA; Gayen JR; Singh SP; Wahajuddin M
    Sci Rep; 2015 Nov; 5():16126. PubMed ID: 26530625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein.
    Cho YA; Choi JS; Burm JP
    Pharmacol Rep; 2011; 63(4):1066-73. PubMed ID: 22001996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro.
    Boocock DJ; Maggs JL; White IN; Park BK
    Carcinogenesis; 1999 Jan; 20(1):153-60. PubMed ID: 9934863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
    Choi JS; Piao YJ; Kang KW
    Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of myricetin on the bioavailability of carvedilol in rats.
    Lee W; Woo ER; Choi JS
    Pharm Biol; 2012 Apr; 50(4):516-22. PubMed ID: 22132944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
    Choi SJ; Shin SC; Choi JS
    Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats.
    Cho YA; Choi DH; Choi JS
    J Pharm Pharmacol; 2009 Jun; 61(6):825-9. PubMed ID: 19505375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats.
    Choi JS; Choi I; Choi DH
    Eur J Drug Metab Pharmacokinet; 2016 Jun; 41(3):231-8. PubMed ID: 25549928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.